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APPLICABILITY AND USEFULNESS OF "CONDITIONED" CHONDROCYTES IN THREE-DIMENSIONAL IN VITRO ARTHRITIS MODELS
M.F. Rai 1 , A. Hauser 1 , T. Graeve 2 , M.F. Schmidt 1 1 Freie Univ. Berlin, Berlin, Germany; 2 Amedrix, Esslingen, Germany Purpose: To evaluate the expediency of an inflammation-sensitive and disease-regulated cyclooxygenase-2 (Cox-2) promoter to exploit therapeutic potential of canine interleukin (IL)-4 gene in vitro. Methods: Chondrocytes from canine knee cartilage were "conditioned" by ex vivo gene transfer using IL-4 as a therapeutic transgene downstream of Cox-2 promoter (devoid of viral sequence). Chondrocyte/scaffold constructs were engineered using two types of biomaterials. The cells were either encapsulated in alginate microspheres or trapped in transplants. The latter were generated by employing a rat-tail collagen type I cartilage regeneration system. Recombinant proinflammatory canine cytokines IL-1β and tumour necrosis factor (TNF)α were used to simulate inflammatory arthritis in chondrocytes within these scaffolds. Multiple inflammation and cartilage markers were monitored to evaluate the antiinflammatory and regulatory characteristics of IL-4. Results: It was shown that in the presence of proinflammatory cytokines, IL-1β and TNFα, the Cox-2 promoter was "switched on" to drive the expression of antiinflammatory IL-4 gene. The controlled and fine-tuned expression of IL-4 down-regulated the inflammatory cytokines such as IL-1β, IL-6, TNFα and enzyme mediators as inducible nitric oxide synthase (iNOS), Cox-2 and matrix metalloproteinases (MMPs)-3 and -13. Synthesis of two major destructive mediators namely nitric oxide (NO) and prostaglandin E2 (PGE2) was also reduced. At the same time, an up-regulated expression of the insulin-like growth factor (IGF)-1, IL-1 receptor antagonist (IL1Ra) and collagen type II was observed. These findings represent proof-of-concept of our previous studies in monolayer cultures. There was virtually no marked difference between the two scaffolds in the context of expression pattern of various marker genes. However, it is tempting to speculate that alginates are easy to use and can enter in small cartilage defects but could be fragile during surgery. On the other hand, the collagen scaffold may be useful to cover larger cartilage lesions. While these results substantiate our previous findings, at the same time they potentiate the need for application of a disease-driven, self-limiting, species-specific therapy for osteoarthritis in vivo. Conclusions: We propose that the application of cytokine therapy based on ex vivo gene transfer through a non-viral, diseaseregulated promoter combined with autologous chondrocyte transplantation could potentially serve as a useful tissue engineering tool towards devising therapeutic strategies for the treatment of osteoarthritis.
HIP JOINT LAVAGE IN OSTEOARTHRITIS: ITS SAFETY AND EFFICACY. EXPERIENCE IN AN OUTPATIENT CARE DEPARTMENT
V. Torrente-Segarra, R. Morla-Novell, A. Acosta-Pereira, M. Lozano-Mateos, A. Cortes-Palacios, A. Rodriguez de la Serna Hosp. de la Santa Creu i Sant Pau, Barcelona, Spain Purpose: Among the rheumatic diseases, osteoarthritis (OA) is the most frequent. Joint lavage is just another way to treat it. It is useful in degenerative and inflammatory diseases. It has been used either in knee and shoulder joints, and it is getting more used as an effectiveness treatment in hip joint. The aim of the hip joint lavage (HJL) is to evacuate fibrin remains and microcrystal, dissolve inflammatory molecules, and, also, induce vasoconstriction through cooling. It is done in a specific box in our outpatient clinics care office. The objective of this study is to evaluate the efficacy and the safety of the HJL after one and three months, in patients affected of OA of the hip. Methods: We recruited 22 patients (22 hips), mean age 70 yearsold, with painful hip OA grades II and III (Kellgren-Lawrence Index), from our outpatient clinics, in Hospital de la Santa Creu I Sant Pau, in Barcelona. We used the Golding technique for the punction, to access the joint, with a 1.1 mm diameter trochar, and using local anesthesy with Mepivacaine 2%. We also performed a 500 cc physiological serums 0.09% perfusion (at 18-20°C) by positive pressure. We also performed a second punction to allow the way out of the serum. The whole intervention took 30 minutes. The efficacy was evaluated by WOMAC, LEQUESNE and Pain-VAS indexes. Statistical analysis was completed by SPSS program. Results: HJL showed efficacy diminishing Pain-VAS mean from basal register to 3-months one (7.33 to 5.33), which represented a significant difference (p<0,001). WOMAC pain domain improved at 3 months, without significant differences, though. The other parameters evaluated are shown separately in the following table, with significant differences between basal and later registers (p=NS). There were no serious adverse events. Two mild complications were seen: local pain during the intervention in one patient, and vagal syndrome in another one. All of them were recovered and we did not need to stop the intervention.
